Article
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Nature communications - 23 Nov 2017
Lauss Martin, Donia Marco, Harbst Katja, Andersen Rikke, Mitra Shamik, Rosengren Frida, Salim Maryem, Vallon-Christersson Johan, Törngren Therese, Kvist Anders, Ringnér Markus, Svane Inge Marie, Jönsson Göran
Abstract excerpt
Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded remarkable response rates and many durable responses in clinical trials in melanoma; however, 50-60% of the patients have no clinical benefit. Here, we searched for predictive biomarkers to ACT in melanoma. Whole exome- and transcriptome sequencing and neoantigen prediction were applied to pre-treatment samples from 27...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.